Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Tyler Kell

Physician Assistant Olathe, KS Physician Assistant

NPI 1598190530 CMS profile 10854284

20805 W 151St St, Suite 224, Olathe, KS 66061

Open in the dashboard

General payments

$2,432

125 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tyler Kell of Olathe, KS is reported in the CMS Open Payments database as having received $2,432 across 125 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $72 4
2024 General $15 1
2023 General $1,664 51
2022 General $649 66
2021 General $33 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tyler Kell
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Tyler Kell were reported at $72. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Tyler Kell Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $33 $132 $37–$438 $132
2022 $649 $155 $48–$522 $149
2023 $1,664 $167 $52–$557 $160
2024 $15 $178 $55–$600 $164
2025 $72 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $1,163 16 payments
  2. Novo Nordisk Inc $341 51 payments
  3. Corcept Therapeutics $256 11 payments
  4. Insulet Corporation $184 9 payments
  5. Dexcom, Inc. $143 8 payments
  6. Xeris Pharmaceuticals, Inc. $125 18 payments
  7. Mannkind Corporation $34 2 payments
  8. Lilly USA, LLC $32 1 payment
  9. AbbVie, Inc. $30 2 payments
  10. Radius Health, Inc. $26 1 payment
  11. Other $98 6 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,485 119 payments
  2. Travel and Lodging $947 6 payments
Products named General payments · program years 2021–2025
  1. MINIMED 780G $1,127 14 payments
  2. Ozempic $341 51 payments
  3. RYBELSUS $341 51 payments
  4. Korlym $256 11 payments
  5. Omnipod $184 9 payments
  6. Dexcom G6 Transmitter $132 7 payments
  7. GVOKE PFS $125 18 payments
  8. AFREZZA $34 2 payments
  9. JARDIANCE $32 1 payment
  10. SYNTHROID $30 2 payments
  11. Other $250 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 47 drugs

Part D claims

3,139

Median for Physician Assistant: 241

Drug cost

$1,779,519

Median for Physician Assistant: $4,110

Branded share of claims

79.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tresiba Flextouch U-200 Insulin Degludec Brand 305 $337,487
Mounjaro Tirzepatide Brand 223 $269,714
Ozempic Semaglutide Brand 200 $248,615
Jardiance Empagliflozin Brand 190 $190,105
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 83 $89,149
Humulin R U-500 Kwikpen Insulin Regular, Human Brand 31 $86,724
Fiasp Flextouch Insulin Aspart (Niacinamide) Brand 114 $84,871
Tresiba Flextouch U-100 Insulin Degludec Brand 111 $61,595
Farxiga Dapagliflozin Propanediol Brand 65 $59,575
Humalog Kwikpen U-200 Insulin Lispro Brand 16 $48,406

The 10 drugs with the highest cost, of 47 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$37,022

Medicare's payments for the services billed

Medicare patients

189

Average age 71

Services billed

943

77 women, 112 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Chronic kidney disease 56%
Ischemic heart disease 49%
Arthritis 43%
Depression 26%
Heart failure 23%
Atrial fibrillation 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

125 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record